Clinical Trial Update: The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock [Phase 2]

View source ↗

Summary

Phase 2 trial completed assessing the safety and efficacy of istaroxime in patients at risk of cardiogenic shock.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Istaroxime (istaroxime)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Cardiogenic Shock | Phase 2 | Status: COMPLETED